Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir in HCV-Infected Liver Transplant Recipients
NCT02781571Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir + velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Cessation of Therapy and Premature Discontinuation Due to Adverse Events at 12 weeks. Started Jul 2016; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02781571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781571.